:: Volume 8, Issue 4 (12-2019) ::
Int J Med Invest 2019, 8(4): 16-22 Back to browse issues page
Promising Role of CD200 Expression in Diagnosis and Prognosis of Chronic Lymphocytic Leukemia: A Review
Mohammad Zahedi, Seyedeh Saeede Kadkhodazade Khorasani, Amirreza Nasirzadeh, Reza Abouali, Mahdi Abounoori, Parham Mortazavi, Reza Sadeghnezhad, Ali Reza Mohseni *
7- Thalassemia Research Center, Hemoglobinopathy institute, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:   (459 Views)
One of the most common leukemia in the world is chronic lymphocytic leukemia (CLL). CLL, as an incurable malignant disorder of B-lymphocytes. CD200, formerly known as OX-2, is a type I glycoprotein that is expressed on a variety of cell types. CD200 plays a vital role in the modulation of the immune system and is upregulated on the surface of numerous tumors, including chronic lymphocytic leukemia. In several studies, it is noted that CD200 was upregulated 1.6- to 5.4-fold in B cells from all patients with B-CLL and may suggest that CD200 upregulation is an early event in the B-CLL disease process. It might conclude that CD200 blocking therapy may be beneficial, and several studies have proven this. We can conclude that CD200 is an excellent prognostic factor that expresses in most CLL patients, and antiCD200 therapeutic interventions can be useful. This literature review article was conducted with the purpose of role of CD200 Expression in the Diagnosis of Chronic Lymphocytic Leukemia.
Keywords: Chronic Lymphocytic Leukemia, Prognosis, CD200, diagnosis
Full-Text [PDF 444 kb]   (99 Downloads)    
Type of Study: Research | Subject: General

XML     Print

Volume 8, Issue 4 (12-2019) Back to browse issues page